NEW YORK, Oct. 12, 2023 /PRNewswire/ -- The Japan regenerative medicine market size is expected to grow by USD 2.33 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 15.89% during the forecast period, according to Technavio's Research. The market is segmented by application (oncology, musculoskeletal, dermatology, and immunology and inflammation and others), and technology (cell, tissue-based, and gene therapy). To gain access to complete details of the market, buy the report!
Company Profile:
Astellas Pharma Inc., Becton Dickinson and Co., CellSeed Inc., Cellusion Inc., Cyfuse Biomedical K.K., F. Hoffmann La Roche Ltd., FUJIFILM Corp., HEALIOS K.K., iHeart Japan Corp., Japan Tissue Engineering Co. Ltd., JCR Pharmaceticals Co. Ltd., MEDINET Co. Ltd., Metcela Inc., Nikon Corp., ROHTO Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., Takara Bio Inc., Takeda Pharmaceutical Co. Ltd., Terumo Corp., and Yokogawa Electric Corp.
Astellas Pharma Inc: The company offers regenerative medicine such as CAR NK, CAR T and Allogeneic CAR, innovative cell therapies for cancer.
- The oncology segment is significant during the forecast period. The main purpose of regenerative therapy is to increase the ability of a patient's immune system to fight cancer. In addition, oncology regenerative medicine treats blood-related diseases such as non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, and leukemia.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View Free PDF Sample Report
"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio
Regenerative Medicine Market In Japan: Driver & Trend:
- Increasing adoption of stem cell therapy drives the market growth during the forecast period. There has been rapid development in stem cell technology which can be applied to regenerative medicine. In addition, the increase in the adoption rate of stem cell technology is due to its use in the treatment of diseases.
- Favorable government regulations for regenerative medicine
- Increasing aging population
Trend
- An increasing number of clinical trials is an emerging trend shaping the growth of the market.
Identify key trends, drivers, and challenges in the market. Download Free sample report to gain access to this information.
Related Reports:
The insomnia therapeutics market size is estimated to grow by USD 1,002.93 million at a CAGR of 5.49% between 2022 and 2027.
The gonorrhea therapeutics market size is estimated to grow by USD 506.68 million at a CAGR of 5.47% between 2022 and 2027.
What are the key data covered in this regenerative medicine market in Japan report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the Japan regenerative medicine market between 2022 and 2027.
- Precise estimation of the Japan regenerative medicine market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of mental health across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of Japan's regenerative medicine market companies.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Application
Market Segmentation by Technology
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
![](https://rt.prnewswire.com/rt.gif?NewsItemId=CG35689&Transmission_Id=202310121430PR_NEWS_USPR_____CG35689&DateId=20231012)
Share this article